I am fortunate to have been in the pigment cell field since my late teens. Over the years, the subject of melanin pigmentation has become more interesting because advances made in biology at the subcellular and molecular levels can be applied to pigment cells, some practical problems have been solved, and the really difficult subjects-those related to melanomas-seem to have some chance of solution. In reciprocal fashion, investigations with pigment cells have helped advance our understanding of biological processes.
Some neoplasms are derived from tissues that are required for life, such as the white blood cells, liver, brain, lungs, and skin. If an attempt to destroy the tissue from which the neoplasm arose eliminated the normal cells as well as the malignant, one would not be left with a viable subject. Other neoplasms, however, arise from cells for which excellent replacement therapy is available: for example, tumors of the thyroid, pituitary and adrenal glands. If an individual has a malignancy of the thyroid gland, removal or destruction of all thyroid tissue could be attempted because replacement therapy for loss of thyroid function would be easy. Finally, some malignancies arise from cells that are not required for life and for which no replacement therapy is essential. Included in this category would be neoplasms of the breast, ovaries, testes, pigment cells, and others. Of course, as yet, we cannot carry out this kind of selective obliteration of a cell type with any great degree of success. But melanocytes behave in ways suggesting that total destruction of all normal and malignant pigment cells in a single patient could be feasible. For example, some people spontaneously develop total vitiligo resulting in destruction of all their melanocytes. The cells disappear. People with vitiligo develop white patches on the hands, face, and other parts of the body. One percent of the population has vitiligo. However, total vitiligo is relatively rare. Theoretically, a person with vitiligo should not develop a melanoma. But in a few known instances subjects with vitiligo have developed melanomas, and some horses with the equivalent of vitiligo frequently have melanomas. We know that the onset of vitiligo after development of a melanoma is significant-occurring in 10-20 percent of patients. A simple goal would be to induce total destruction of normal and malignant pigment cells in a controlled manner. We cannot do that at present even though patients with vitiligo lose nonmalignant melanocytes with ease. To achieve our goal we must first understand a tremendous amount of basic biology. The hope that such information will come forth provides the stimulus for having this nonclinical and nonapplied conference on pigment cell biology.
